Identification of B-cell epitopes on structural proteins VP1 and VP2 of Senecavirus A and development of a multi-epitope recombinant protein vaccine

Virology. 2023 May:582:48-56. doi: 10.1016/j.virol.2023.03.015. Epub 2023 Mar 30.

Abstract

Senecavirus A (SVA) is an important pathogenic cause of vesicular disease in pigs worldwide. In this study, we screened the B-cell epitopes of SVA using a bioinformatics approach combined with an overlapping synthetic polypeptide method. Four dominant B-cell epitopes (at amino acid (aa) positions: 7-26, 48-74, 92-109, and 129-144) from the VP1 protein and five dominant B-cell epitopes (aa: 38-57, 145-160, 154-172, 193-208, 249-284) from the VP2 protein were identified. Multi-epitope genes comprising the identified B-cell epitope domains were synthesized, prokaryotic expressed, and purified, and their immune protection efficacy was evaluated in piglets. Our results showed that the multi-epitope recombinant protein rP2 induced higher neutralizing antibodies and provided 80% protection against homologous SVA challenge. Thus, the B-cell epitope peptides identified in this study are potential candidates for SVA vaccine development, and rP2 may offer safety and efficacy in controlling infectious SVA.

Keywords: B-cell epitope; Immune protection; Multi-epitope vaccine; Piglets; Senecavirus A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • Epitopes, B-Lymphocyte* / genetics
  • Peptides
  • Picornaviridae* / genetics
  • Swine
  • Vaccines, Synthetic

Substances

  • Epitopes, B-Lymphocyte
  • Antibodies, Neutralizing
  • Vaccines, Synthetic
  • Peptides

Supplementary concepts

  • Senecavirus A